At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 48 enrolled
Drug / intervention
Sintilimab +2 moredrug
Likely dose
Sintilimab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Clinical Trial Evaluating Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Sintilimab, Chidamide, and 1 other intervention for Advanced Microsatellite Stable Colorectal Cancer and Metastatic Microsatellite-stable Colorectal Cancer. Targeting 48 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide in combination with or without IBI305(bevacizumab) in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionJul 2022
Study CompletionDec 2023
TodayJul 2026
First PostedJan 26, 2021
Enrollment StartMar 11, 2021
Primary CompletionJul 26, 2022
Study CompletionDec 1, 2023
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
Sintilimabdrug
200mg IV on Day 1 Q3W
Chidamidedrug
30mg PO BIW each 3-week cycle
IBI305drug
7.5mg/kg IV on Day 1 Q3W